These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 23125283)

  • 21. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.
    Nikonova EV; Xiong Y; Tanis KQ; Dawson VL; Vogel RL; Finney EM; Stone DJ; Reynolds IJ; Kern JT; Dawson TM
    Hum Mol Genet; 2012 Jan; 21(1):163-74. PubMed ID: 21972245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
    Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
    J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The screening of the 3'UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease.
    Cardo LF; Coto E; Ribacoba R; Mata IF; Moris G; Menéndez M; Alvarez V
    J Hum Genet; 2014 Jun; 59(6):346-8. PubMed ID: 24758914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.
    Braunger LJ; Knab F; Gasser T
    J Parkinsons Dis; 2024; 14(5):977-991. PubMed ID: 38848197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
    Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
    Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
    Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
    Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
    Weng YH; Chen CY; Lin KJ; Chen YL; Yeh TH; Hsiao IT; Chen IJ; Lu CS; Wang HL
    Exp Neurol; 2016 Jan; 275 Pt 1():104-15. PubMed ID: 26363496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease.
    Botta-Orfila T; Morató X; Compta Y; Lozano JJ; Falgàs N; Valldeoriola F; Pont-Sunyer C; Vilas D; Mengual L; Fernández M; Molinuevo JL; Antonell A; Martí MJ; Fernández-Santiago R; Ezquerra M
    J Neurosci Res; 2014 Aug; 92(8):1071-7. PubMed ID: 24648008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A trojan horse for Parkinson's disease.
    Hu Y; Tong Y
    Sci Signal; 2010 Apr; 3(116):pe13. PubMed ID: 20371768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
    Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
    J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
    Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
    J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
    Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
    Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.
    Gómez-Suaga P; Rivero-Ríos P; Fdez E; Blanca Ramírez M; Ferrer I; Aiastui A; López De Munain A; Hilfiker S
    Hum Mol Genet; 2014 Dec; 23(25):6779-96. PubMed ID: 25080504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
    Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
    Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
    Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.